NO20021719L - 6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament - Google Patents

6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament

Info

Publication number: NO20021719L
Authority: NO; Norway
Prior art keywords: drug; preparation; position substituted; substituted indolines; indolines
Prior art date: 1999-10-13

Application number

NO20021719A

Other languages

English (en)

Other versions

NO20021719D0 (no

NO322746B1 (no

Inventor

Armin Heckel

Gerald Juergen Roth

Rainer Walter

Jacobus Van Meel

Norbert Redemann

Ulrike Tontsch-Grunt

Walter Spevak

Frank Hilberg

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-13

Filing date

2002-04-11

Publication date

2002-04-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021719(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-13 Priority claimed from DE19949208A external-priority patent/DE19949208A1/de

2000-08-31 Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de

2002-04-11 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2002-04-11 Publication of NO20021719D0 publication Critical patent/NO20021719D0/no

2002-04-11 Publication of NO20021719L publication Critical patent/NO20021719L/no

2006-12-04 Publication of NO322746B1 publication Critical patent/NO322746B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20021719A 1999-10-13 2002-04-11 Indoliner, substituert i 6-stilling, og farmasoytisk preparat, samt anvendelse og fremstilling derav. NO322746B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19949208A DE19949208A1 (de)	1999-10-13	1999-10-13	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de)	2000-08-31	2000-08-31	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de)	1999-10-13	2000-10-09	In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (3)

Publication Number	Publication Date
NO20021719D0 NO20021719D0 (no)	2002-04-11
NO20021719L true NO20021719L (no)	2002-04-11
NO322746B1 NO322746B1 (no)	2006-12-04

Family

ID=26006858

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20021719A NO322746B1 (no)	1999-10-13	2002-04-11	Indoliner, substituert i 6-stilling, og farmasoytisk preparat, samt anvendelse og fremstilling derav.
NO2015009C NO2015009I1 (no)	1999-10-13	2015-03-18	Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
NO2023033C NO2023033I1 (no)	1999-10-13	2023-09-05	Nintedanib

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2015009C NO2015009I1 (no)	1999-10-13	2015-03-18	Nintedanib, tautomere og salter derav, spesielt Nintedanib og fysiologiske akseptable salter derav, spesielt Nintedanib esilat; 3-Z-[l-(4-(N-((4-metylpiperazin-1-yl)-metylkarbonyl)-N-metylamino)- anilino)-1-fenylmetylen]-6-metoksykarbonyl-2-indolinon - Se blant annet kravene 1, 2, 5 (t) og 6 i basispatentet
NO2023033C NO2023033I1 (no)	1999-10-13	2023-09-05	Nintedanib

Country Status (43)

Country	Link
EP (2)	EP1224170B9 (no)
JP (2)	JP4021664B2 (no)
KR (2)	KR100835546B1 (no)
CN (1)	CN100455568C (no)
AR (1)	AR026036A1 (no)
AT (1)	ATE439342T1 (no)
AU (1)	AU781939B2 (no)
BE (1)	BE2015C018I2 (no)
BG (1)	BG65983B1 (no)
BR (1)	BRPI0014735B8 (no)
CA (1)	CA2387013C (no)
CO (1)	CO5261488A1 (no)
CY (2)	CY1110067T1 (no)
CZ (1)	CZ301073B6 (no)
DE (1)	DE50015711D1 (no)
DK (1)	DK1224170T5 (no)
EA (1)	EA006080B1 (no)
EE (1)	EE05427B1 (no)
EG (1)	EG25931A (no)
ES (1)	ES2331459T3 (no)
FR (1)	FR15C0024I2 (no)
HK (1)	HK1052505B (no)
HR (1)	HRP20020306B1 (no)
HU (2)	HU230416B1 (no)
IL (2)	IL148756A0 (no)
LT (1)	LTC1224170I2 (no)
LU (1)	LU92681I2 (no)
ME (1)	MEP45408A (no)
MX (1)	MXPA02002799A (no)
MY (1)	MY127956A (no)
NL (1)	NL300725I2 (no)
NO (3)	NO322746B1 (no)
NZ (1)	NZ518489A (no)
PE (1)	PE20010671A1 (no)
PL (1)	PL207445B1 (no)
PT (1)	PT1224170E (no)
RS (1)	RS51013B (no)
SA (1)	SA01210704B1 (no)
SI (1)	SI1224170T1 (no)
SK (1)	SK287312B6 (no)
TW (1)	TWI268922B (no)
UA (1)	UA75054C2 (no)
WO (1)	WO2001027081A1 (no)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19816624A1 (de) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1415987B1 (en)	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Nitrogenous aromatic ring compounds as anti cancer agents
US6638965B2 (en)	2000-11-01	2003-10-28	Boehringer Ingelheim Pharma Kg	Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de)	2001-04-06	2002-10-10	Boehringer Ingelheim Pharma	In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7678805B2 (en)	2001-06-29	2010-03-16	Ab Science	Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
US7727731B2 (en)	2001-06-29	2010-06-01	Ab Science	Potent, selective and non toxic c-kit inhibitors
JP2004536097A (ja) *	2001-06-29	2004-12-02	アブサイエンス	自己免疫疾患を治療するためのチロシンキナーゼ阻害剤の使用法
EP1401415B1 (en)	2001-06-29	2006-06-21	AB Science	Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
US20030091974A1 (en) *	2001-06-29	2003-05-15	Alain Moussy	Method for screening compounds capable of depleting mast cells
CA2452371A1 (en)	2001-06-29	2003-01-09	Ab Science	Use of tyrosine kinase inhibitors for treating allergic diseases
US20030225152A1 (en) *	2001-09-27	2003-12-04	Andrews Steven W.	3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
US6797825B2 (en)	2001-12-13	2004-09-28	Abbott Laboratories	Protein kinase inhibitors
RU2316554C2 (ru)	2001-12-27	2008-02-10	Тереванс, Инк.	Производные индолина, используемые как ингибиторы протеинкиназы
SE0302546D0 (sv)	2003-09-24	2003-09-24	Astrazeneca Ab	New compounds
ITBO20020198A1 (it) *	2002-04-12	2003-10-13	Univ Bologna	Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7514468B2 (en)	2002-07-23	2009-04-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en)	2002-07-23	2007-01-30	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de)	2002-07-24	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en)	2002-08-16	2004-10-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) *	2002-08-16	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) *	2002-09-12	2006-12-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) *	2002-11-27	2012-02-22	アラーガン、インコーポレイテッド	疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005044788A1 (ja)	2003-11-11	2005-05-19	Eisai Co., Ltd.	ウレア誘導体およびその製造方法
SE0401790D0 (sv) *	2004-07-07	2004-07-07	Forskarpatent I Syd Ab	Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) *	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US8772269B2 (en)	2004-09-13	2014-07-08	Eisai R&D Management Co., Ltd.	Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1797877A4 (en)	2004-09-13	2010-12-15	Eisai Co Ltd	JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
AU2005283422C1 (en)	2004-09-17	2017-02-02	Eisai R & D Management Co., Ltd.	Medicinal composition
PE20060777A1 (es) *	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP2281901B1 (en)	2005-08-02	2013-11-27	Eisai R&D Management Co., Ltd.	Anti-tumour pharmaceutical composition with angiogenesis inhibitors
WO2007057397A1 (en) *	2005-11-15	2007-05-24	Boehringer Ingelheim International Gmbh	Treatment of cancer
WO2007136103A1 (ja)	2006-05-18	2007-11-29	Eisai R & D Management Co., Ltd.	甲状腺癌に対する抗腫瘍剤
EP1870400A1 (en) *	2006-06-08	2007-12-26	Boehringer Ingelheim Pharma GmbH & Co. KG	Salts and crystalline salt forms of an 2-indolinone derivative
WO2008026748A1 (en)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en)	2007-01-29	2015-01-14	Eisai R&D Management Co., Ltd.	Composition for treatment of undifferentiated-type of gastric cancer
US20100184747A1 (en) *	2007-06-12	2010-07-22	Boehringer Ingelheim International Gmbh	Indoline derivatives and their use in treating disease-states such as cancer
ES2435454T3 (es)	2007-06-21	2013-12-19	Janssen Pharmaceutica, N.V.	Indolin-2-onas y aza-indolin-2-onas
CA2704000C (en)	2007-11-09	2016-12-13	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (es) *	2007-12-03	2009-10-19	Boehringer Ingelheim Int	Derivados de indolinona y procedimiento para su fabricacion
ES2658091T3 (es) *	2007-12-03	2018-03-08	Boehringer Ingelheim International Gmbh	Procedimiento para la fabricación de un derivado de indolinona
SI2985025T1 (en)	2008-06-06	2018-04-30	Boehringer Ingelheim International Gmbh	A pharmaceutical combination
TW201011002A (en)	2008-07-29	2010-03-16	Boehringer Ingelheim Int	New compounds
EP2387401A1 (en)	2009-01-14	2011-11-23	Boehringer Ingelheim International GmbH	Method for treating colorectal cancer
US8802384B2 (en)	2009-03-12	2014-08-12	Boehringer Ingelheim International Gmbh	Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
EP2429520A1 (en)	2009-05-14	2012-03-21	Boehringer Ingelheim International GmbH	New combination therapy in treatment of oncological and fibrotic diseases
ES2564797T3 (es)	2009-08-19	2016-03-29	Eisai R&D Management Co., Ltd.	Composición farmacéutica con contenido en un derivado de quinolina
US20120107304A1 (en)	2010-04-27	2012-05-03	Boehringer Ingelheim International Gmbh	Combination therapy in treatment of oncological and fibrotic diseases
RU2560683C2 (ru)	2010-06-25	2015-08-20	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
WO2012068441A2 (en)	2010-11-19	2012-05-24	Ratiopharm Gmbh	Intedanib salts and solid state forms thereof
MX2013009931A (es)	2011-04-18	2013-10-01	Eisai R&D Man Co Ltd	Agentes terapeuticos contra tumores.
ES2705950T3 (es)	2011-06-03	2019-03-27	Eisai R&D Man Co Ltd	Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
DK2807160T3 (da)	2012-01-26	2019-10-14	Angion Biomedica Corp	Antifibrotiske forbindelser og anvendelser deraf
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
HK1214830A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型ntrk1融合分子及其应用
WO2014086102A1 (zh)	2012-12-06	2014-06-12	山东亨利医药科技有限责任公司	作为酪氨酸激酶抑制剂的吲哚满酮衍生物
WO2014098176A1 (ja)	2012-12-21	2014-06-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体のアモルファス及びその製造方法
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
US20140350022A1 (en)	2013-05-10	2014-11-27	Boehringer Ingelheim International Gmbh	Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
RU2658601C2 (ru)	2013-05-14	2018-06-21	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
CN104003925B (zh) *	2013-06-05	2016-03-30	四川大学	吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) *	2013-07-18	2015-01-22	Concert Pharmaceuticals, Inc.	Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
JP6799201B2 (ja)	2013-07-31	2020-12-16	アヴァリンファーマインク．	エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
ES2926687T3 (es)	2014-08-28	2022-10-27	Eisai R&D Man Co Ltd	Derivado de quinolina muy puro y método para su producción
CN104262232B (zh) *	2014-09-09	2016-05-04	苏州明锐医药科技有限公司	尼泰达尼的制备方法
RS65049B1 (sr)	2015-02-25	2024-02-29	Eisai R&D Man Co Ltd	Metoda za suzbijanje gorčine derivata kinolina
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en)	2015-05-06	2016-11-10	Suven Life Sciences Limited	Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) *	2015-06-05	2017-03-08	北京康立生医药技术开发有限公司	一锅法制备尼达尼布的合成方法
ES2971096T3 (es)	2015-06-06	2024-06-03	Cloudbreak Therapeutics Llc	Composiciones y métodos para tratar el terigio
CA2988707C (en)	2015-06-16	2023-10-10	Eisai R&D Management Co., Ltd.	Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105126909B (zh) *	2015-07-13	2018-01-23	淮海工学院	固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs)	2015-07-29	2021-03-03	Zentiva, K.S.	Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) *	2015-08-14	2017-03-01	廊坊百瑞化工有限公司	一种一锅煮法合成尼达尼布关键中间体的新方法
ES2887426T3 (es)	2015-08-20	2021-12-22	Eisai R&D Man Co Ltd	Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
WO2017109513A1 (en)	2015-12-24	2017-06-29	Respivert Limited	Indolinones compounds and their use in the treatment of fibrotic diseases
CZ2016104A3 (cs)	2016-02-24	2017-09-06	Zentiva, K.S.	Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
WO2017153748A1 (en)	2016-03-08	2017-09-14	Respivert Limited	Indole derivatives and their use as protein kinase inhibitors
US20190160054A1 (en)	2016-04-13	2019-05-30	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en)	2016-05-19	2017-11-22	Boehringer Ingelheim International Gmbh	Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
JP2019522638A (ja)	2016-05-27	2019-08-15	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
US20190275033A1 (en)	2016-06-01	2019-09-12	Boehringer Ingelheim International Gmbh	Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
KR20240052865A (ko)	2016-06-02	2024-04-23	에이디에스 테라퓨틱스 엘엘씨	녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법
MX395539B (es)	2016-07-29	2025-03-25	Oncternal Therapeutics Inc	Usos de compuestos de indolinona
CN106748961A (zh) *	2016-11-30	2017-05-31	瑞阳制药有限公司	尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) *	2016-11-30	2017-05-31	瑞阳制药有限公司	尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
CN110062625A (zh)	2016-12-12	2019-07-26	勃林格殷格翰国际有限公司	尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
JP6581320B2 (ja)	2017-02-08	2019-09-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療用医薬組成物
JP2020512364A (ja)	2017-03-28	2020-04-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	筋ジストロフィーの処置方法において使用するためのニンテダニブ
RU2019134940A (ru)	2017-05-16	2021-06-16	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Лечение гепатоцеллюлярной карциномы
EP3700529B1 (en)	2017-10-23	2025-07-09	Boehringer Ingelheim International GmbH	New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
WO2019097112A1 (en)	2017-11-17	2019-05-23	Fermion Oy	Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (ja) *	2018-04-05	2022-04-28	国立大学法人大分大学	慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) *	2018-05-07	2018-08-03	日照市普达医药科技有限公司	一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
KR20210013574A (ko)	2018-05-25	2021-02-04	클라우드브레이크 테라퓨틱스, 엘엘씨	안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법
WO2020070331A1 (en) *	2018-10-05	2020-04-09	Ichnos Sciences S.A.	Indolinone compounds for use as map4k1 inhibitors
WO2021198253A1 (en)	2020-04-01	2021-10-07	Boehringer Ingelheim International Gmbh	Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (zh) *	2020-08-24	2021-09-24	江西国药有限责任公司	一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) *	2020-12-14	2022-07-01	成都大学	吲哚酮衍生物及其制药用途
EP4541368A3 (en)	2021-01-25	2025-07-02	Nibec Co., Ltd.	Peptide for preventing and treating fibrosis
EP4098246A1 (en)	2021-05-31	2022-12-07	Lotus Pharmaceutical Co., Ltd.	Formulation of nintedanib
CN115703758B (zh) *	2021-08-12	2024-03-26	中国医学科学院药物研究所	一类用作激酶抑制剂的化合物及其制备方法和用途
WO2024037982A1 (en)	2022-08-16	2024-02-22	Boehringer Ingelheim International Gmbh	Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (zh) *	2023-09-28	2024-10-01	國立臺灣大學	用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL96047C (no) *	1956-06-08
JP2742333B2 (ja) *	1994-05-06	1998-04-22	アルコンラボラトリーズ，インコーポレイテッド	眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
EP0815859B1 (en) *	1996-01-17	2003-06-18	Taiho Pharmaceutical Company Limited	Intimal thickening inhibitors
GB9718913D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Substituted oxindole derivatives
DE19815020A1 (de) *	1998-04-03	1999-10-07	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) *	1998-04-15	1999-10-21	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de)	1998-06-04	1999-12-09	Boehringer Ingelheim Pharma	Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds

2000
- 2000-09-10 UA UA2002053890A patent/UA75054C2/uk unknown
- 2000-10-09 DE DE50015711T patent/DE50015711D1/de not_active Expired - Lifetime
- 2000-10-09 RS YUP-266/02A patent/RS51013B/sr unknown
- 2000-10-09 SI SI200031039T patent/SI1224170T1/sl unknown
- 2000-10-09 IL IL14875600A patent/IL148756A0/xx active IP Right Grant
- 2000-10-09 HU HU0204587A patent/HU230416B1/hu active Protection Beyond IP Right Term
- 2000-10-09 WO PCT/EP2000/009867 patent/WO2001027081A1/de not_active Ceased
- 2000-10-09 ES ES00971347T patent/ES2331459T3/es not_active Expired - Lifetime
- 2000-10-09 JP JP2001530102A patent/JP4021664B2/ja not_active Expired - Lifetime
- 2000-10-09 PL PL355433A patent/PL207445B1/pl not_active IP Right Cessation
- 2000-10-09 EE EEP200200197A patent/EE05427B1/xx active Protection Beyond IP Right Term
- 2000-10-09 KR KR1020027004701A patent/KR100835546B1/ko not_active Expired - Lifetime
- 2000-10-09 EA EA200200380A patent/EA006080B1/ru not_active IP Right Cessation
- 2000-10-09 BR BRPI0014735-4 patent/BRPI0014735B8/pt active IP Right Grant
- 2000-10-09 HR HR20020306A patent/HRP20020306B1/xx not_active IP Right Cessation
- 2000-10-09 NZ NZ518489A patent/NZ518489A/en not_active IP Right Cessation
- 2000-10-09 CA CA002387013A patent/CA2387013C/en not_active Expired - Lifetime
- 2000-10-09 CZ CZ20021410A patent/CZ301073B6/cs unknown
- 2000-10-09 EP EP00971347.0A patent/EP1224170B9/de not_active Expired - Lifetime
- 2000-10-09 AT AT00971347T patent/ATE439342T1/de active
- 2000-10-09 EP EP09164507A patent/EP2157081A1/de not_active Withdrawn
- 2000-10-09 KR KR1020077017807A patent/KR100857734B1/ko not_active Expired - Lifetime
- 2000-10-09 DK DK00971347.0T patent/DK1224170T5/en active
- 2000-10-09 AU AU10233/01A patent/AU781939B2/en not_active Expired
- 2000-10-09 CN CNB008158681A patent/CN100455568C/zh not_active Expired - Lifetime
- 2000-10-09 SK SK646-2002A patent/SK287312B6/sk not_active IP Right Cessation
- 2000-10-09 HK HK03104649.4A patent/HK1052505B/zh not_active IP Right Cessation
- 2000-10-09 PT PT00971347T patent/PT1224170E/pt unknown
- 2000-10-09 MX MXPA02002799A patent/MXPA02002799A/es active IP Right Grant
- 2000-10-09 ME MEP-454/08A patent/MEP45408A/xx unknown
- 2000-10-11 MY MYPI20004762A patent/MY127956A/en unknown
- 2000-10-11 EG EG2000101293A patent/EG25931A/xx active
- 2000-10-11 PE PE2000001088A patent/PE20010671A1/es not_active IP Right Cessation
- 2000-10-12 TW TW089121320A patent/TWI268922B/zh not_active IP Right Cessation
- 2000-10-12 CO CO00077925A patent/CO5261488A1/es not_active Application Discontinuation
- 2000-10-13 AR ARP000105394A patent/AR026036A1/es active IP Right Grant
2001
- 2001-02-06 SA SA01210704A patent/SA01210704B1/ar unknown
2002
- 2002-03-19 IL IL148756A patent/IL148756A/en active Protection Beyond IP Right Term
- 2002-04-05 BG BG106587A patent/BG65983B1/bg unknown
- 2002-04-11 NO NO20021719A patent/NO322746B1/no active Protection Beyond IP Right Term
2007
- 2007-08-15 JP JP2007211755A patent/JP2007302697A/ja active Pending
2009
- 2009-11-06 CY CY20091101152T patent/CY1110067T1/el unknown
2015
- 2015-03-13 CY CY2015009C patent/CY2015009PI1/el unknown
- 2015-03-16 LT LTPA2015015C patent/LTC1224170I2/lt unknown
- 2015-03-16 NL NL300725C patent/NL300725I2/nl unknown
- 2015-03-16 FR FR15C0024C patent/FR15C0024I2/fr active Active
- 2015-03-16 LU LU92681C patent/LU92681I2/xx unknown
- 2015-03-16 BE BE2015C018C patent/BE2015C018I2/fr unknown
- 2015-03-18 NO NO2015009C patent/NO2015009I1/no unknown
2016
- 2016-05-13 HU HUS1600022C patent/HUS1600022I1/hu unknown
2023
- 2023-09-05 NO NO2023033C patent/NO2023033I1/no unknown

Also Published As

Publication number	Publication date
HRP20020306A2 (en)	2003-10-31
IL148756A (en)	2007-10-31
CY2015009PI2 (el)	2016-12-14
DK1224170T5 (en)	2018-01-22
BRPI0014735A (pt)	2002-07-16
AR026036A1 (es)	2002-12-26
BG65983B1 (bg)	2010-08-31
JP2003511441A (ja)	2003-03-25
EP2157081A1 (de)	2010-02-24
PT1224170E (pt)	2009-10-01
NO20021719D0 (no)	2002-04-11
KR100835546B1 (ko)	2008-06-09
NO322746B1 (no)	2006-12-04
EA006080B1 (ru)	2005-08-25
KR20020038949A (ko)	2002-05-24
AU781939B2 (en)	2005-06-23
DK1224170T3 (da)	2009-12-07
EA200200380A1 (ru)	2002-10-31
BE2015C018I2 (no)	2019-10-23
SI1224170T1 (sl)	2009-12-31
HU230416B1 (hu)	2016-05-30
HUP0204587A2 (en)	2003-05-28
HUP0204587A3 (en)	2004-07-28
EE200200197A (et)	2003-06-16
SA01210704B1 (ar)	2006-12-05
SK6462002A3 (en)	2002-08-06
EP1224170B9 (de)	2017-11-22
ES2331459T3 (es)	2010-01-05
BG106587A (bg)	2003-01-31
WO2001027081A1 (de)	2001-04-19
EP1224170B1 (de)	2009-08-12
TWI268922B (en)	2006-12-21
PL207445B1 (pl)	2010-12-31
PL355433A1 (pl)	2004-04-19
RS51013B (sr)	2010-10-31
HUS1600022I1 (hu)	2017-02-28
EG25931A (en)	2012-10-24
LU92681I9 (no)	2019-01-03
KR100857734B1 (ko)	2008-09-10
CO5261488A1 (es)	2003-03-31
NO2015009I2 (no)	2015-03-18
IL148756A0 (en)	2002-09-12
EP1224170A1 (de)	2002-07-24
HK1052505A1 (en)	2003-09-19
CN100455568C (zh)	2009-01-28
LTPA2015015I1 (lt)	2015-04-27
HRP20020306B1 (en)	2010-09-30
CY1110067T1 (el)	2015-01-14
PE20010671A1 (es)	2001-06-28
BRPI0014735B8 (pt)	2021-07-06
NO2015009I1 (no)	2015-03-30
FR15C0024I2 (fr)	2016-08-26
UA75054C2 (uk)	2006-03-15
CA2387013A1 (en)	2001-04-19
CN1391557A (zh)	2003-01-15
NL300725I2 (nl)	2017-07-13
JP2007302697A (ja)	2007-11-22
AU1023301A (en)	2001-04-23
CA2387013C (en)	2009-12-29
SK287312B6 (sk)	2010-06-07
LU92681I2 (fr)	2015-05-18
YU26602A (sh)	2004-11-25
MEP45408A (en)	2011-02-10
HK1052505B (zh)	2009-06-26
MXPA02002799A (es)	2003-02-27
DE50015711D1 (de)	2009-09-24
CZ301073B6 (cs)	2009-10-29
NO2023033I1 (no)	2023-09-05
BRPI0014735B1 (pt)	2012-07-10
EE05427B1 (et)	2011-06-15
CZ20021410A3 (cs)	2002-07-17
FR15C0024I1 (no)	2015-04-17
NZ518489A (en)	2005-05-27
MY127956A (en)	2007-01-31
JP4021664B2 (ja)	2007-12-12
KR20070095996A (ko)	2007-10-01
ATE439342T1 (de)	2009-08-15
CY2015009PI1 (el)	2016-12-14
LTC1224170I2 (lt)	2023-11-10

Publication	Publication Date	Title
NO20021719L (no)	2002-04-11	6-posisjon substituerte indoliner, fremstilling og anvendelse derav som medikament
DK1218341T3 (da)	2005-12-12	Sulfonylcarboxamid-derivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
NO20012567D0 (no)	2001-05-25	Azepinoindolderivater, fremstilling og anvendelse derav
NO20021689L (no)	2002-05-30	5-leddede heterocykliske derivater, fremstilling derav og anvendelse som medikamenter
DK1095025T3 (da)	2003-04-07	Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
DK1953162T3 (da)	2012-09-10	Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel.
DK1083171T3 (da)	2004-08-09	Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
NO20025879D0 (no)	2002-12-06	Acylfenylureaderivater, fremgangsmåte for fremstilling derav og deres anvendelse som et legemiddel
NO20006138D0 (no)	2000-12-01	Substituerte indolinoner, fremstilling og anvendelse derav som medikamenter
NO20011503D0 (no)	2001-03-23	Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
NO20014702L (no)	2001-09-27	Diarylderivater og deres anvendelse som medikamenter
NO20005146D0 (no)	2000-10-13	Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
NO20024749D0 (no)	2002-10-02	Indolin-2-on-derivater, deres fremstilling og anvendelse som ocytocin reseptor ligander
DK1161434T3 (da)	2003-05-26	Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1230230T3 (da)	2003-12-15	Derivater af indeno-dihydrothiazol, fremstilling deraf og anvendelse som anorektiske lægemidler
NO20023146L (no)	2002-06-28	Substituerte fenyl-piperazinderivater, deres fremstilling og anvendelse
DK1043307T3 (da)	2003-09-22	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1523473T3 (da)	2013-06-03	Indolinderivater substitueret i position 6, deres fremstilling og anvendelse som lægemiddel.
NO20010219L (no)	2001-03-15	Polycykliske tiazolidin-2-ylidenaminer, fremgangsmÕte for deres fremstilling og deres anvendelse som legemiddel
DK1157020T3 (da)	2003-01-27	Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-2-benzazocin-10-oler, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
NO20001782L (no)	2000-10-09	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1235809T3 (da)	2004-03-15	Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
NO20015617L (no)	2002-01-15	Spiroimidazolderivater, deres fremstilling, deres anvendelse og farmasöytiske preparater som innbefatter slike derivater
NO20020404D0 (no)	2002-01-25	Streptograminderivater, deres produksjon og forbindelser derav
IS6391A (is)	2002-05-21	2-Arýlkínólín afleiður, framleiðsla og meðferðarleg notkun á þeim

Legal Events

Date	Code	Title	Description
2015-03-30	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: VARGATEF, NINTEDANIB; REG. NO/DATE: EU/1/14/954-001-004 20141201 Spc suppl protection certif: 2015009 Filing date: 20150318
2017-01-09	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: NINTEDANIB, TAUTOMERE OG SALTER DERAV, SPESIELT NINTEDANIB OG FYSIOLOGISKE AKSEPTABLE SALTER DERAV, SPESIELT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/954-001-004 20141201 Spc suppl protection certif: 2015009 Filing date: 20150318 Extension date: 20251009
2020-11-09	MK1K	Patent expired
2023-09-18	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: NINTEDANIB; REG. NO/DATE: EU/1/14/954-001-004 20141201 Spc suppl protection certif: 2023033 Filing date: 20230905